Journal
UROLOGIC CLINICS OF NORTH AMERICA
Volume 33, Issue 2, Pages 201-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ucl.2005.12.010
Keywords
-
Categories
Funding
- NIDDK NIH HHS [R01 DK60957, R01 DK059142] Funding Source: Medline
Ask authors/readers for more resources
Advanced and metastatic prostate cancers remain potentially lethal tumors. Although androgen deprivation therapy remains the most effective treatment, patients who progress to androgen independence die of their disease. This article focuses on the mechanisms by which hormone resistance develops, including the reactivation of androgen receptor during androgen deprivation therapy, the role of cancer stem cells, and the emergence of epithelial-mesenchymal transition cells, which have increased metastatic potential. It is through an enhanced understanding of these mechanisms that new therapies can be developed to combat this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available